Godavari Drugs has scheduled its 38th Annual General Meeting for September 25, 2026, to seek shareholder approval for entering the nutraceuticals and dietary supplements business. The company has also fixed the book closure period from September 19 to September 25, 2026.

The board previously approved an alteration to the Memorandum of Association (MoA) to authorize this new line of business. The amendment requires a Special Resolution under Section 13 of the Companies Act, 2013. Shareholders will vote via electronic means during the designated e-voting window.

Book Closure and Voting Schedule

The Register of Members and Share Transfer Books will remain closed from September 19, 2026 to September 25, 2026 (both days inclusive). This closure determines the members entitled to vote at the meeting. The cut-off date for ascertaining eligible shareholders is September 18, 2026.

Shareholders holding shares in physical or dematerialized form can cast their votes electronically. For shareholders whose email addresses are not registered with the company or its Registrar and Transfer Agent (CIL Securities Ltd), the AGM notice is accessible on the company website and BSE platform.

Strategic Rationale

The existing main objects clause covers drugs and pharmaceuticals but does not explicitly authorize the proposed nutraceutical segment. This new business is governed under the Food Safety and Standards Act, 2006.

The alteration enables Godavari Drugs to validly carry out domestic and export marketing, third-party contract manufacturing, and own manufacturing of bulk ingredients and formulations in this sector. The change is additive in nature and does not involve discontinuing any existing business activities.

Shareholder Approval Process

The resolution will be placed before members at the 38th AGM, which will be held via Video Conferencing or Other Audio Visual Means. The amendment does not affect the existing rights of members or the nature of their liability.

Upon member approval, the company will file Form MGT-14 with the Registrar of Companies, Telangana, to effectuate the change.

Godavari Drugs reported no deviation or variation in the utilisation of funds raised through its preferential issue for the quarter ended June 30, 2026. The company raised a total of ₹4,411.73 lakh on March 18, 2026, and confirmed that the funds were deployed strictly according to the originally disclosed objects.

The Board of Directors considered and approved the Statement on Deviation or Variation in Utilisation of Funds at its meeting held on August 14, 2026. The filing was submitted to the BSE Limited pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Fund Utilisation Breakdown

The preferential issue proceeds were allocated across three primary objects: capital expenditure, working capital requirements, and repayment of unsecured loans to promoters and directors. During the quarter, the company utilised funds only for capital expenditure purposes.

The capital expenditure was directed towards manufacturing Active Pharmaceutical Ingredients (APIs), intermediates, and specialty chemicals in therapeutic categories including Anti-HIV and CNS segments. Specific utilisations included civil construction for production blocks, procurement and installation of equipment such as reactors and heat exchangers, and augmentation of electrical infrastructure.

Compliance and Oversight

The Audit Committee reviewed the statement and recorded no comments, indicating compliance with the approved fund utilisation plan. Similarly, the auditors provided no comments on the deviation report. No monitoring agency was appointed for this issue.

There were no modifications to the original objects of the fund raising, nor any changes in the terms of the contract as disclosed in the fund raising documents. Consequently, no shareholder approval was required for variations during this quarter.